M&A / Deals Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions pharminent April 17, 2026
M&A / Deals Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions pharminent April 17, 2026
M&A / Deals Obesity’s explosive growth continues as Q1 deals exceed total 2025 value pharminent April 16, 2026
M&A / Deals Terremoto wins $108m in Series C to drive cancer and rare disease programmes pharminent April 16, 2026
M&A / Deals Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers pharminent April 15, 2026
M&A / Deals Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico pharminent April 15, 2026
M&A / Deals BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut pharminent April 15, 2026
M&A / Deals AbbVie enters world of pain in up to $715M deal with China’s Haisco pharminent April 13, 2026
M&A / Deals Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors pharminent April 10, 2026
M&A / Deals Roche and C4 Therapeutics to advance degrader-antibody conjugates research pharminent April 10, 2026
M&A / Deals Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation pharminent April 10, 2026
M&A / Deals Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb pharminent April 9, 2026
M&A / Deals Roche sticks with C4T, adding up to $1B for molecular glue partnership pharminent April 9, 2026
M&A / Deals Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors pharminent April 9, 2026
M&A / Deals With 3 quick buyouts, Gilead leans into its latest transformation pharminent April 8, 2026
M&A / Deals Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities pharminent April 8, 2026
M&A / Deals Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic pharminent April 8, 2026
